La Jolla, CA, United States of America

Lucas Rascon

USPTO Granted Patents = 7 

Average Co-Inventor Count = 8.3

ph-index = 2

Forward Citations = 5(Granted Patents)


Location History:

  • La Jolla, CA (US) (2019 - 2023)
  • San Diego, CA (US) (2024)

Company Filing History:


Years Active: 2019-2025

Loading Chart...
7 patents (USPTO):Explore Patents

Title: Innovations and Contributions of Lucas Rascon

Introduction

Lucas Rascon is a prominent inventor based in La Jolla, California. He has made significant contributions to the field of immunotherapy, holding a total of seven patents. His work focuses on developing innovative solutions for treating various diseases, including cancer and autoimmune disorders.

Latest Patents

Among his latest patents is the CLL-1 targeted immunotherapies. This invention provides improved CLL-1 targeting polypeptides and compositions for adoptive T cell therapies aimed at treating, preventing, or ameliorating symptoms of cancer, infectious diseases, autoimmune diseases, inflammatory diseases, and immunodeficiencies. Another notable patent is the multivalent and multispecific OX40-binding fusion proteins. This invention relates to molecules that specifically engage OX40, a member of the TNF receptor superfamily, and focuses on multivalent and multispecific molecules that bind to OX40.

Career Highlights

Lucas Rascon has worked with several companies, including Inhibrx Biosciences, Inc. and Inhibrx, Inc. His experience in these organizations has allowed him to further his research and development in the field of immunotherapy.

Collaborations

He has collaborated with notable professionals in his field, including Brendan P Eckelman and John C Timmer. These collaborations have contributed to the advancement of his innovative projects.

Conclusion

Lucas Rascon's work in immunotherapy showcases his dedication to advancing medical science through innovation. His patents reflect a commitment to improving treatment options for various diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…